AKT-mediated regulation of chromatin ubiquitylation and tumorigenesis through Mel18 phosphorylation.
Jia MaiXiao-Dan PengJun TangTian DuYu-Hong ChenZi-Feng WangHai-Liang ZhangJun-Hao HuangZhuo-Yan ZhongDong YangZhi-Ling LiYun HuangGong-Kan FengXiao-Feng ZhuRong DengPublished in: Oncogene (2021)
Polycomb repressor complex 1 (PRC1) is linked to the regulation of gene expression and histone ubiquitylation conformation, which contributes to carcinogenesis. However, the upstream regulators of PRC1 biogenesis machinery remain obscure. Here, we report that the polycomb group-related mammalian gene Mel18 is a target of the protein kinase AKT. AKT phosphorylates Mel18 at T334 to disrupt the interaction between Mel18 and other PRC1 members, leading to attenuated PRC1-dependent ubiquitylation of histone H2A at Lys119. As such, PRC1 target genes, many of which are known oncogenes, are derepressed upon T334-Mel18 phosphorylation, which promotes malignant behaviours, including cell proliferation, tumour formation, migration and invasion, bone and brain metastatic lesion formation. Notably, a positive correlation between AKT activity and pT334-Mel18 is observed, and prognostic models based on p-AKT and pT334-Mel18 that predicted overall survival and distant metastasis-free survival in breast cancer patients are established. These findings have implications for understanding the role of AKT and its associated proteins in chromatin ubiquitylation, and also indicate the AKT-Mel18-H2AK119ub axis as a novel prognostic biomarker and therapeutic target for cancer patients.
Keyphrases
- cell proliferation
- signaling pathway
- gene expression
- free survival
- genome wide
- protein kinase
- dna methylation
- cell cycle
- pi k akt
- dna damage
- squamous cell carcinoma
- transcription factor
- small cell lung cancer
- oxidative stress
- lymph node
- white matter
- resting state
- brain injury
- copy number
- genome wide identification
- drug induced
- functional connectivity
- bone loss